The Global Biosimulation Market experienced significant revenue growth in 2022, reaching USD 2.78 billion, and is projected to maintain a compound annual growth rate (CAGR) of 16% in the coming years, as stated in the latest report by Reports and Data. Biosimulation has emerged as an increasingly valuable tool in the field of drug development, offering the potential to predict the safety and effectiveness of drug candidates. This capability eliminates the need for extensive clinical trials, resulting in substantial time and cost savings for pharmaceutical companies. https://www.reportsanddata.com/report-detail/biosimulation-market